Work

A Phase 2 Study of TAK-659, an Investigational Reversible Dual SYK/FLT3 Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Year: 2019

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2019-125650

Authors: Tycel J. Phillips, Gilles Salles, Daniel J. Landsburg, Giuseppe Gritti, Krish Patel, Herve Tilly, Catherine Thieblemont, William Townsend, Silvia Ferrari, Kate F. Stumpo, Shilpi Katyayan, Cheryl Li, Harry Miao, Igor Proscurshim, Ajay K. Gopal

Institutions: U-M Rogel Cancer Center, Hôpital Lyon Sud, Abramson Cancer Center, University of Pennsylvania, Ospedale Papa Giovanni XXIII, Inserm, Centre Henri Becquerel, Hôpital Saint-Louis, University College Hospital, University College London Hospitals NHS Foundation Trust, Takeda Oncology (United States), Cytel (United States), Seattle Cancer Care Alliance, University of Washington, Fred Hutch Cancer Center

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2985221104

Cites:

Cited by: 3

Related to: 10